CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

Open access

Abstract

Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of many solid tumors. However, the clinical efficacy of immune checkpoint therapy is limited to a subset of patients with specific tumor types 1,2. Multiple clinical trials with combinatorial immune checkpoint strategies are ongoing; however, the mechanistic rationale for tumor-specific targeting of immune checkpoints is elusive. To garner an insight into tumor-specific immunomodulatory targets, we analyzed 94 patients representing five different cancer types, including those that respond relatively well to immune checkpoint therapy and those that do not, such as glioblastoma multiforme, prostate cancer and colorectal cancer. Through mass cytometry and single-cell RNA sequencing, we identified a unique population of CD73 hi macrophages in glioblastoma multiforme that persists after anti-PD-1 treatment. To test if targeting CD73 would be important for a successful combination strategy in glioblastoma multiforme, we performed reverse translational studies using CD73-/- mice. We found that the absence of CD73 improved survival in a murine model of glioblastoma multiforme treated with anti-CTLA-4 and anti-PD-1. Our data identified CD73 as a specific immunotherapeutic target to improve antitumor immune responses to immune checkpoint therapy in glioblastoma multiforme and demonstrate that comprehensive human and reverse translational studies can be used for rational design of combinatorial immune checkpoint strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0694-x

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 365

Metadata

Authors
Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., Ott, M., Kong, L. Y., Heimberger, A. B., de Groot, J., Sepesi, B., Overman, M., Kopetz, S., Allison, J. P., Pe’er, D., & Sharma, P.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • German Cancer Research Center (DE)
  • NYU Langone Health (US)
Corresponding author
Sharma, Padmanee
Venue
Nature Medicine
Published
2019-12-23
Volume
26
Issue
1
Pages
39-46
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2995345254
Cited by
356
References
47
Citations by year
2026: 21 · 2025: 53 · 2024: 43 · 2023: 63 · 2022: 65 · 2021: 76 · 2020: 35
FWCI
18.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Parker Foundation
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Keywords
CD73, glioblastoma, immune checkpoint therapy, anti-PD-1, anti-CTLA-4, tumor-associated macrophages, tumor immune microenvironment, combination immunotherapy, antitumor immunity, prostate cancer, colorectal cancer
MeSH terms
Algorithms, Animals, Brain Neoplasms, Disease Models, Animal, Glioblastoma, Humans, Immunotherapy, Macrophages, Magnetic Resonance Imaging, Mice, Inbred C57BL, 5'-Nucleotidase, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, Myeloid Cells, Cell Line, Tumor, GPI-Linked Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. https://app.cochat.ai/papers/10.1038/s41591-019-0694-x
The paper
Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., Ott, M., Kong, L. Y., Heimberger, A. B., de Groot, J., Sepesi, B., Overman, M., Kopetz, S., Allison, J. P., Pe’er, D., & Sharma, P. (2020). Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine. https://doi.org/10.1038/s41591-019-0694-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.